[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"t-cell-non-hodgkin-lymphoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:t-cell-non-hodgkin-lymphoma":56},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,43,73,99,117],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100627624","phase-1-cd45be-hspc--cart-45-cells-100627624",false,"NCT07451054","CD45BE-HSPC + CART-45 Cells","Phase 1 Study of Autologous Anti-CD45 CAR T Cells in Combination With CD45 Base Edited HSPCs in Patients With Relapsed or Refractory Hematologic Malignancies","Inclusion Criteria:\n\n1\\. Signed informed consent form 2. Male or females age ≥ 18 years 3. Disease-Specific Criteria\n\na. B-cell Non-Hodgkin Lymphoma (B-cell NHL)- including the following sub-types:\n\ni. Patients with any of the following large B-cell lymphoma diagnoses who meet the prior treatment criteria outlined below: Diffuse Large B-cell Lymphoma not otherwise specified (DLBCL NOS); Primary Cutaneous DLBCL; Primary Mediastinal (thymic) Large B-cell Lymphoma; ALK+ Anaplastic Large B-cell Lymphoma; High-Grade B-cell Lymphoma with MYC and BCL2 and\u002For BCL6 rearrangements (i.e., \"Double or Triple Hit\"); High-grade B-cell Lymphoma, NOS; T-cell Rich B-cell Lymphoma; Transformed Follicular Lymphoma; or any aggressive B-cell lymphoma arising from indolent lymphoma.\n\n1\\. Patients must have either failed\u002Frelapsed after, or be ineligible for, prior commercial CAR T cell therapy; AND 2. Relapsed\u002Frefractory disease after at least 2 prior lines of appropriate therapy.\n\nii. Follicular Lymphoma\n\n1. Patients must have either failed\u002Frelapsed after, or be ineligible for, prior commercial CAR T cell therapy; AND\n2. Relapsed\u002Frefractory disease after at least 2 prior lines of systemic therapy (not including a single agent monoclonal antibody therapy).\n\niii. Mantle Cell Lymphoma\n\n1. Patients must have either failed\u002Frelapsed after, or be ineligible for, prior commercial CAR T cell therapy; AND\n2. Relapsed\u002Frefractory disease after at least 2 prior lines of systemic therapy, including a Bruton tyrosine kinase (TKI) inhibitor. Single-agent monoclonal antibody therapy does not count towards prior lines of therapy.\n\n   iv. Marginal Zone Lymphoma- relapsed\u002Frefractory disease after at least 2 prior lines of appropriate therapy, including a Bruton tyrosine kinase (TKI) inhibitor. Note: Single-agent monoclonal antibody therapy does not count towards prior lines of therapy.\n\n   b. T-cell Non-Hodgkin Lymphoma (T-cell NHL)\n\n   i. Histologically or cytologically confirmed relapsed or refractory (r\u002Fr) mature aggressive T- and NK-cell neoplasms as defined in the 5th edition of the WHO Classification of Hematolymphoid tumors, which includes any of the following diagnoses:\n\n   • Peripheral T-cell Lymphoma, NOS (PTCL-NOS);\n\n   • Nodal T-cell Lymphomas with T Follicular Helper \\[TFH\\] Phenotype, including Follicular T cell Lymphoma, Angioimmunoblastic Lymphoma, or Anaplastic Large Cell Lymphoma (ALCL);\n\n   • ALK+ or ALK-, Enteropathy-Associated T-cell Lymphoma (EATL);\n\n   • Monomorphic Epitheliotropic Intestinal T-cell Lymphoma (MEITL);\n\n   • Extranodal NK\u002FT-cell Lymphoma;\n\n   • Primary Cutaneous T-cell Lymphoma (CTCL);\n\n   • Transformed Mycosis Fungoides (tMF) without blood involvement;\n\n   • Primary Cutaneous Aggressive Epidermotropic CD8+ Cytotoxic T-Cell Lymphoma;\n\n   • Subcutaneous Panniculitis-like T-cell Lymphoma.\n\n   ii. Must have received at least one prior line of systemic therapy for their lymphoma. Additional prior treatment provisions required for the following indications:\n\n1\\. Participants with Anaplastic Large Cell Lymphoma (ALCL) must have received prior Brentuximab vedotin, unless contraindicated.\n\n2\\. Participants with Subcutaneous Panniculitis-like T-cell Lymphoma or Transformed Mycosis Fungoides (tMF) must have received at least 2 prior lines of systemic therapy.\n\nc. Hodgkin Lymphoma (HL)\n\ni. Patients with histologically proven classical Hodgkin Lymphoma that is CD45 positive by IHC or flow cytometry by a CLIA certified laboratory; AND\n\nii. Relapsed\u002Frefractory disease after at least 2 prior lines of therapy which must include the following:\n\n1. Brentuximab vedotin and immune checkpoint inhibitors (unless contraindicated); AND\n2. Autologous stem cell transplant (unless patient has chemorefractory disease to salvage treatment) d. Large Cell Transformation of CLL (Richter's Transformation) i. Patients must be primary refractory or received at least 1 prior line of treatment for Richter's Transformation.\n\n4\\. Patients are appropriate candidates for autologous HSCT as per physician-investigator clinical discretion\n\n5\\. Patients with relapsed disease after prior allogeneic SCT must meet the following criteria:\n\na. Have no active GVHD and require no immunosuppression\n\nb. Are more than 6 months from transplant at the time of physician-investigator confirmation of eligibility\n\n6\\. Adequate organ function defined as:\n\n1. Serum creatinine ≤ 1.5x ULN or estimated creatinine clearance ≥ 35 mL\u002Fmin and not on dialysis\n2. ALT\u002FAST ≤ 3 x ULN\n3. Direct bilirubin ≤ 2.0 mg\u002Fdl; for patients with Gilbert's syndrome direct bilirubin must be ≤ 3.0 mg\u002Fdl\n4. Left Ventricular Ejection Fraction (LVEF) ≥ 40% confirmed by ECHO\u002FMUGA\n5. DLCO \\> 45% predicted value; adjusted for level of hemoglobin\n6. Must have minimum level of pulmonary reserve defined as ≤ Grade 1 dyspnea and pulse oxygen \\> 92% on room air 7. ECOG Performance Status 0-1\n\nExclusion Criteria:\n\n1. Active hepatitis B or hepatitis C infection\n2. Any active, uncontrolled infection.\n3. Class III\u002FIV cardiovascular disability according to the New York Heart Association Classification.\n4. Clinically apparent arrhythmia or arrhythmias that are not stable on medical management within two weeks of physician-investigator confirmation of eligibility.\n5. Severe, active co-morbidity that, in the opinion of the physician-investigator, would preclude participation in this study.\n6. Prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen.\n7. Active acute or chronic GVHD requiring systemic therapy.\n8. Dependence on systemic steroids or immunosuppressant medications. For additional details regarding use of steroid and immunosuppressant medications.\n9. Active CNS involvement. Patients with a history of CNS involvement that was successfully treated are eligible. A CNS evaluation is only required for eligibility if a subject is experiencing signs\u002Fsymptoms of CNS involvement.\n10. Patients with evidence of a circulating T-cell malignancy as measured by flow cytometry.\n11. History of allergy or hypersensitivity to study product excipients (human serum albumin, DMSO, and Dextran 40).\n12. Active autoimmune disease requiring systemic immunosuppressive treatment equivalent to ≥ 10mg of prednisone. Patients with autoimmune neurologic diseases (such as MS) will be excluded.\n13. Pregnant or nursing (lactating) patients. Participants of reproductive potential must agree to use acceptable birth control methods.","ALL","18 Years",{"count":19,"type":20},42,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","This is a phase 1, open-label, dose-finding study to assess the safety, feasibility, pharmacokinetics and preliminary efficacy of autologous base edited anti-CD45 CAR T cells (referred to as \"CART-45 cells\") following an autologous transplant of CD45 base edited hematopoietic stem and progenitor cells (referred to as \"CD45BE-HSPC\") in patients with relapsed or refractory hematologic malignancies.",[26,27,28,29],"B-Cell Non-Hodgkin Lymphoma (NHL)","Richter's Transformation","T-Cell Non-Hodgkin Lymphoma","Hodgkin Lymphoma","RECRUITING","2026-06-08",{"date":33,"type":34},"2026-06-10","ACTUAL",{"date":36,"type":20},"2026-07",{"date":38,"type":20},"2051-07",{"name":40,"class":41},"University of Pennsylvania","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":53,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":72},"100548368","phase-1-cd5-deleted-chimeric-antigen-receptor-cells-senza5-cart5-for-t-cell-non-hodgkin-lymphoma-nhl-100548368","NCT06420089","CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)","CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) to Enhance Immunotherapy Against T Cell Non-Hodgkin Lymphoma (NHL): a First-in-human Phase I Clinical Trial","VIPER101","Inclusion Criteria:\n\n1. Histologically or cytologically confirmed relapsed or refractory (r\u002Fr) CD5-positive nodal peripheral T-cell lymphoma (such as peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS), nodal T-cell lymphomas with T-follicular helper (TFH) phenotype, including follicular T cell lymphoma, angioimmunoblastic lymphoma, or anaplastic large cell lymphoma) or other non-leukemic CD5+ aggressive mature T cell lymphomas (such as enteropathy-associated T cell lymphoma, monomorphic epitheliotropic intestinal T cell lymphoma, transformed mycosis fungoides, primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma, primary cutaneous insert gamma delta symbols lymphoma, or subcutaneous panniculitis like T cell lymphoma).\n2. ≥50% expression of CD5 on flow cytometry or IHC on malignant cells on the most recent biopsy\n3. Must have received at least one line of prior systemic therapy for their lymphoma; participants with anaplastic large cell lymphoma (ALCL) must have received prior brentuximab unless there was a contraindication to brentuximab.\n4. Evaluable disease defined by at least one lesion that can be measured in least 1 dimension and measures at least 1.5 cm in its longest dimension by CT or PET scan, or bone\u002Fbone marrow involvement, or skin involvement.\n5. No circulating CD5+ malignant cells identified by peripheral blood flow cytometry must be present.\n\nExclusion Criteria:\n\n1. Pregnant or lactating (nursing) women.\n2. HIV infection.\n3. Concurrent use of systemic steroids or immunosuppressant medications.\n4. Any uncontrolled active medical disorder that would preclude participation as outlined.\n5. History of immunodeficiency.\n6. History of prior chimeric antigen receptor therapy (CAR T), autologous or syngeneic HCT \\\u003C100 days from transplant at the time of cell infusion or previous allo-HCT.\n7. Active and\u002For systemic inflammatory or autoimmune diseases.\n8. Signs or symptoms indicative of active CNS involvement.\n9. Known history or prior diagnosis of optic neuritis or other immunologic or inflammatory disease affecting the central nervous system, and unrelated to lymphoma or previous lymphoma treatment.\n10. Clinically apparent arrhythmia, or arrhythmias that are not stable on medical management\n11. Current participation in or prior participation in a study of an investigational agent or using an investigational device within 2 weeks of the first dose of treatment.\n12. Prior monoclonal antibody therapy within 4 weeks prior to study Day 1\n13. Prior use of alemtuzumab\n14. Prior chemotherapy targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1\n15. Uncontrolled active infection requiring systemic therapy.\n16. Circulating CD5+ malignant cells identified by peripheral blood flow cytometry present.\n17. Active and\u002For systemic inflammatory or autoimmune diseases.",{"count":52,"type":20},30,[23],"This is an open-label phase I study to determine the safety and recommended phase 2 dose (RP2D) of Senza5 CART5 cells in patients with relapsed or refractory CD5 positive nodal T cell NHL. RP2D will be based on the safety, tolerability, pharmacokinetics, and preliminary efficacy of Senza5 CART5 cells. This trial will evaluate up to 5 dose levels using the Bayesian Optimal Interval (BOIN) design enrolling 3 patients in each cohort to assess safety and achieve therapeutic levels so that the RP2D of Senza5 CART5 cells given as a single IV infusion can be determined.",[56],"T Cell Non-Hodgkin Lymphoma",[58,59,60,61],"T Cell Lymphoma","Lymphoma","CD5KO CART5","Senza5 CART","2025-11-05",{"date":64,"type":34},"2025-11-10",{"date":66,"type":34},"2024-10-04",{"date":68,"type":20},"2029-08-30",{"name":70,"class":71},"Vittoria Biotherapeutics","INDUSTRY",2,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":21,"phases":84,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":98},"100594708","phase-1-cd5-car-t-cell-therapy-for-rr-t-cell-lymphomas-100594708","NCT07022964","CD5 CAR T-Cell Therapy for r\u002Fr T-cell Lymphomas","A Multicenter, Open-Label, Non-Randomized, Single-Arm Phase I\u002FII Clinical Study of Autologous and New Donor CD7 CAR-T Cells for Relapsed or Refractory Mature T-Cell Lymphomas","Inclusion Criteria (Patients who met all the inclusion criteria were eligible for enrolment):\n\n* Relapsed or refractory CD7-positive T-cell lymphomas that were treated with with standard chemotherapy, with poor prognosis from currently available treatments at and no available treatment options (e.g., HSCT or chemotherapy);\n* Male or female, age 14-70;\n* Eastern Cooperative Oncology Group (ECOG) Physical Status Score 0-2;\n* life expectancy is at least 60 days;\n* Subjects should be capable of understanding and signing the informed consent form prior to any screening procedures. Subjects are willing to follow the study visit schedule and associated study procedures as specified in the protocol. Candidates between the ages of 19-70 years old will need to be sufficiently aware of and capable of signing the informed consent form; underage candidates between the ages of 14-18 years old will need to be sufficiently aware of the informed consent form and their legal guardian will also need to sign the informed consent form separately.\n\nExclusion Criteria (Patients who fulfil any of the following criteria may not be enrolled):\n\n* Patients with history of allogeneic HSCT but PBMNC is not available from prior- transplant donor for preparation of CAR T cells and peripheral blood tumour load \\>30%; patients without history of allogeneic HSCT and peripheral blood tumour load \\>30%;\n* Intracranial hypertension or cerebral impaired consciousness;\n* Symptomatic heart failure or severe arrhythmia;\n* Symptoms of severe respiratory failure;\n* With other types of malignancy;\n* Diffuse intravascular coagulation;\n* Serum creatinine and\u002For urea nitrogen ≥ 1.5 times the normal value;\n* With sepsis or other uncontrollable infection;\n* Suffering from uncontrollable diabetes mellitus;\n* Severe mental disorders;\n* Have significant intracranial lesions on cranial MRI;\n* Organ transplantation (excluding haematopoietic stem cell transplantation) history;\n* Female patients (patients of childbearing potential) with positive blood HCG test;\n* Hepatitis (including hepatitis B and C) and positive screening for AIDS and syphilis.","14 Years","70 Years",{"count":83,"type":20},36,[23,85],"PHASE2","This is a multi-center, open-label, non-randomized, single-arm clinical trial. Refractory\u002Frelapse T-NHL patients are treated with autologous and allogeneic CD5 CAR T-cell therapy. The primary objective is to prospectively evaluate the safety of CD5 CAR T cell bridging to HSCT in the treatment of r\u002Fr T-NHL. The primary endpoint is the type and incidence of dose limiting toxicity (DLT) within 21 days after CD5 CAR-T cell infusion. A total of 36 subjects is estimated to be enrolled.",[28,88],"T-cell Lymphoma (PTCL and CTCL)","2025-06-08",{"date":91,"type":34},"2025-06-15",{"date":93,"type":34},"2025-06-01",{"date":95,"type":20},"2028-06-01",{"name":97,"class":41},"Beijing GoBroad Hospital",3,{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":80,"maxAge":81,"enrollmentInfo":104,"targetDuration":4,"studyType":21,"phases":105,"briefSummary":106,"conditions":107,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":116},"100587213","phase-1-cd7-car-t-cell-therapy-for-rr-t-cell-lymphomas-100587213","NCT06925464","CD7 CAR T-Cell Therapy for r\u002Fr T-cell Lymphomas",{"count":83,"type":20},[23,85],"This is a multi-center, open-label, non-randomized, single-arm clinical trial. Refractory\u002Frelapse T-NHL patients are treated with autologous and allogeneic CD7 CAR T-cell therapy. The primary objective is to prospectively evaluate the safety of CD7 CAR T cell bridging to HSCT in the treatment of r\u002Fr T-NHL. The primary endpoint is the type and incidence of dose limiting toxicity (DLT) within 21 days after CD7 CAR-T cell infusion. A total of 36 subjects is estimated to be enrolled.",[28,88],"2025-05-11",{"date":110,"type":34},"2025-05-13",{"date":112,"type":34},"2025-04-01",{"date":114,"type":20},"2027-04-01",{"name":97,"class":41},4,{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":123,"eligibilityCriteria":124,"healthyVolunteers":125,"sex":16,"minAge":126,"maxAge":127,"enrollmentInfo":128,"targetDuration":4,"studyType":21,"phases":130,"briefSummary":131,"conditions":132,"keywords":135,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":72},"100274987","phase-2-allogeneic-stem-cell-transplantation-in-relapsedrefractory-t--nkt-cell-lymphomas-100274987","NCT02859402","Allogeneic Stem Cell Transplantation in Relapsed\u002FRefractory T-, NK\u002FT-cell Lymphomas","Allogeneic Stem Cell Transplantation With 3-days Busulfan Plus Fludarabine as Conditioning in Patients With Relapsed or Refractory T-, NK\u002FT-cell Lymphomas","RRTCLAlloSCT","Inclusion Criteria:\n\n1. Age 19 - 65\n2. Histologically confirmed T or NK cell lymphomas :\n\n   * anaplastic large cell lymphoma\n   * angioimmunoblastic T-cell lymphoma,\n   * peripheral T-cell lymphoma, NOS\n   * NK\u002FT-cell lymphoma\n3. Relapsed after or refractory to one or more of previous chemotherapy including frontline autologous HSCT.\n4. At least one measured lesion using conventional CT or PET CT at the time of relapse after or refractory to one or more of previous chemotherapy and before salvage chemotherapy\n5. Complete or Partial response after short cycles of salvage chemotherapy\n6. Patients who have HLA full-match (8\u002F8 in HLA-A, B, C, DR by DNA high-resolution technique) or one-locus mismatch (7\u002F8) sibling, or unrelated bone marrow or peripheral blood or cord blood stem cell donors\n7. ECOG performance status ≤ 2\n8. Charlson Comorbidity Index (CCI) before HSCT ≤ 3\n9. Adequate renal function : serum creatinine level \\\u003C 2.0 mg\u002FdL\n10. Adequate liver function :\n\n    * Transaminase (AST\u002FALT) \\\u003C 3 X upper normal value (or \\\u003C 5 x ULN in the presence of lymphoma involvement of the liver)\n    * Total bilirubin \\\u003C 2 X upper normal value (or \\\u003C 5 x ULN in the presence of NK\u002FT involvement of the liver)\n11. Cardiac ejection fraction ≥ 50 % as measured by MUGA or 2D ECHO without clinically significant abnormality\n12. No clinically significant infection\n13. No clinically significant bleeding symptoms or sign\n14. Patients who decided to participate in this study and signed for a written consent\n\nExclusion Criteria:\n\n1. Adult T cell leukemia\u002Flymphoma, Lymphoblastic lymphoma, Primary cutaneous CD30+ T cell disorders Mycosis fungoides, Sezary SD\n2. Patients who have previously performed Allo-HSCT\n3. T cell lymphoma with primary central nervous system (CNS) Involvement.\n\n   \\*\\* However, patients who have only had prophylactic intrathecal or intravenous chemotherapy against CNS disease are eligible.\n4. Patients with a known history of HIV seropositivity or HCV (+).\n\n   \\*\\* Patients with HBV are eligible. However, primary prophylaxis using antiviral agents is recommended for HBV carrier or prevent HBV reactivation during whole treatment period.\n5. Any other malignancies within the past 5 years\n\n   \\*\\* Except curatively treated non-melanoma skin cancer or in situ carcinoma of cervix uteri\n6. Ejection fraction \\\u003C 50% by a echocardiography\n7. FEV1 \\\u003C60% or DLCO \\\u003C60% by a pulmonary function test\n8. ECOG performance status 3 or 4\n9. Combined serious medical problem or disease\n\n   * Serious or unstable heart disease although proper treatment\n   * Myocardial infarction in recent 3 months\n   * Underlying serious neurologic or psychiatric disease including dementia or seizure\n   * Active uncontrolled infection including hepatitis B and C\n   * Serious other medical problems observed by the doctors in charge of the patient\n10. Pregnant or lactating women, women of childbearing potential not employing adequate contraception",true,"19 Years","65 Years",{"count":129,"type":20},34,[85],"Relapsed and refractory T-cell lymphomas have been reported to have dismal outcomes. The role of allogeneic stem cell transplantation have been demonstrated in these patients. This clinical trial is studying the efficacy and safety of busulfan plus fludarabine as conditioning therapy followed by allogeneic stem cell transplantation (Allo-SCT) in T- and NK\u002FT-cell lymphoma patients who have relapsed or are refractory to previous chemotherapies including autologous transplantation.",[133,134],"T-cell Non-Hodgkin Lymphoma","Lymphoma, Extranodal NK-T-Cell",[133,136,137,138,139],"NK\u002FT-cell Non-Hodgkin Lymphoma","Relapsed, refractory","Conditioning","Allogeneic stem cell transplantation","2022-08-17",{"date":142,"type":34},"2022-08-18",{"date":144,"type":34},"2016-12",{"date":146,"type":20},"2027-12",{"name":148,"class":41},"Keimyung University Dongsan Medical Center"]